Health Care [ 11/12 ] | Biotechnology [ 66/75 ]
NASDAQ | Common Stock
VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease.
It offers hepatitis B (HBV) vaccine under the PreHevbrio, PreHevbri, and Sci-B-Vac brand names.
The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma cancer vaccine immunotherapeutic candidate; VBI-1501, a prophylactic cytomegalovirus vaccine candidate; and VBI-2501 to treat Zika virus.
In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905.
The company has collaboration and license agreements with Brii Biosciences Limited, the National Research Council of Canada, and Coalition for Epidemic Preparedness Innovations.
The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016.
VBI Vaccines Inc. is based in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 15, 24 | -0.73 Increased by +77.33% | -0.53 Decreased by -37.74% |
| Mar 27, 24 | -0.01 Increased by +87.50% | -0.22 Increased by +95.45% |
| Nov 14, 23 | -1.01 Decreased by -1.02 K% | -0.14 Decreased by -621.43% |
| Aug 14, 23 | -5.05 Decreased by -2.71 K% | -2.16 Decreased by -133.80% |
| May 15, 23 | -3.22 Decreased by -3.92 K% | -1.25 Decreased by -157.60% |
| Mar 13, 23 | -0.08 Decreased by -14.29% | -0.07 Decreased by -14.29% |
| Nov 10, 22 | -0.09 Decreased by -50.00% | -0.08 Decreased by -12.50% |
| Aug 8, 22 | -0.18 Decreased by -157.14% | -0.07 Decreased by -157.14% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 1.21 M Increased by +150.31% | -17.90 M Increased by +52.17% | Decreased by -1.47 K% Increased by +80.89% |
| Dec 31, 23 | 853.00 K Increased by +191.13% | -13.00 K Increased by +99.93% | Decreased by -1.52% Increased by +99.98% |
| Sep 30, 23 | 6.62 M Increased by +1.99 K% | -20.44 M Increased by +27.18% | Decreased by -308.64% Increased by +96.52% |
| Jun 30, 23 | 720.00 K Increased by +108.09% | -44.63 M Increased by +33.98% | Decreased by -6.20 K% Increased by +68.27% |
| Mar 31, 23 | 485.00 K Increased by +284.92% | -37.42 M Decreased by -45.91% | Decreased by -7.72 K% Increased by +62.09% |
| Dec 31, 22 | 293.00 K Increased by +261.73% | -19.64 M Decreased by -4.54% | Decreased by -6.70 K% Increased by +71.10% |
| Sep 30, 22 | 317.00 K Increased by +196.26% | -28.07 M Decreased by -77.16% | Decreased by -8.86 K% Increased by +40.20% |
| Jun 30, 22 | 346.00 K Increased by +143.66% | -67.59 M Decreased by -286.78% | Decreased by -19.54 K% Decreased by -58.74% |